Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

被引:231
作者
Liu, Liming [1 ]
机构
[1] MRL, Dept Pharmacokinet Pharmacodynam & Drug Metab, West Point, PA 19486 USA
关键词
monoclonal antibody (mAb); Fc-fusion protein; pharmacokinetics; FcRn; target-mediated drug disposition (TMDD); glycosylation; anti-drug antibody (ADA); human PK prediction; MEDIATED DRUG DISPOSITION; PROJECTING HUMAN PHARMACOKINETICS; TERMINAL N-ACETYLGLUCOSAMINE; NECROSIS-FACTOR RECEPTOR; MURINE IGG1 MOLECULE; CYNOMOLGUS MONKEYS; HALF-LIFE; THERAPEUTIC PROTEINS; BINDING-PROPERTIES; ASIALOGLYCOPROTEIN RECEPTOR;
D O I
10.1007/s13238-017-0408-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc engineering, IgG-FcRn interaction can be used to generate a variety of therapeutic antibodies with significantly enhanced half-life or ability to remove unwanted antigen from circulation. Glycosylation of a mAb or Fc-fusion protein can have a significant impact on the PK of these molecules. mAb charge can be important and variants with pI values of 1-2 unit difference are likely to impact PK with lower pI values being favorable for a longer half-life. Most mAbs display target mediated drug disposition (TMDD), which can have significant consequences on the study designs of preclinical and clinical studies. The PK of mAb can also be influenced by anti-drug antibody (ADA) response and off-target binding, which require careful consideration during the discovery stage. mAbs are primarily absorbed through the lymphatics via convection and can be conveniently administered by the subcutaneous (sc) route in large doses/volumes with co-formulation of hyaluronidase. The human PK of a mAb can be reasonably estimated using cynomolgus monkey data and allometric scaling methods.
引用
收藏
页码:15 / 32
页数:18
相关论文
共 142 条
[1]   Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody [J].
Abuqayyas, Lubna ;
Zhang, Xiaoyan ;
Balthasar, Joseph P. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 444 (1-2) :185-192
[2]   Determination of critical quality attributes for monoclonal antibodies using quality by design principles [J].
Alt, Nadja ;
Zhang, Taylor Y. ;
Motchnik, Paul ;
Taticek, Ron ;
Quarmby, Valerie ;
Schlothauer, Tilman ;
Beck, Hermann ;
Emrich, Thomas ;
Harris, Reed J. .
BIOLOGICALS, 2016, 44 (05) :291-305
[3]   The impact of glycosylation on the biological function and structure of human immunoglobulins [J].
Arnold, James N. ;
Wormald, Mark R. ;
Sim, Robert B. ;
Rudd, Pauline M. ;
Dwek, Raymond A. .
ANNUAL REVIEW OF IMMUNOLOGY, 2007, 25 :21-50
[4]   CARBOHYDRATE-SPECIFIC RECEPTORS OF THE LIVER [J].
ASHWELL, G ;
HARFORD, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 1982, 51 :531-554
[5]   A Guide to Rational Dosing of Monoclonal Antibodies [J].
Bai, Shuang ;
Jorga, Karin ;
Xin, Yan ;
Jin, Denise ;
Zheng, Yanan ;
Damico-Beyer, Lisa A. ;
Gupta, Manish ;
Tang, Meina ;
Allison, David E. ;
Lu, Dan ;
Zhang, Yi ;
Joshi, Amita ;
Dresser, Mark J. .
CLINICAL PHARMACOKINETICS, 2012, 51 (02) :119-135
[6]   Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up [J].
Bartelds, Geertje M. ;
Krieckaert, Charlotte L. M. ;
Nurmohamed, Michael T. ;
van Schouwenburg, Pauline A. ;
Lems, Willem F. ;
Twisk, Jos W. R. ;
Dijkmans, A. C. ;
Aarden, Lucien ;
Wolbink, Gerrit Jan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (14) :1460-1468
[7]   Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors [J].
Bertolotti-Ciarlet, Andrea ;
Wang, Weirong ;
Lownes, Rebecca ;
Pristatsky, Pavlo ;
Fang, Yulin ;
McKelvey, Troy ;
Li, Yingzhe ;
Li, Yunsong ;
Drummond, James ;
Prueksaritanont, Thomayant ;
Vlasak, Josef .
MOLECULAR IMMUNOLOGY, 2009, 46 (8-9) :1878-1882
[8]   Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen [J].
Bittner, B. ;
Richter, W. F. ;
Hourcade-Potelleret, F. ;
McIntyre, C. ;
Herting, F. ;
Zepeda, M. L. ;
Schmidt, J. .
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (09) :401-409
[9]   A recombinant human enzyme for enhanced interstitial transport of therapeutics [J].
Bookbinder, L. H. ;
Hofer, A. ;
Haller, M. F. ;
Zepeda, M. L. ;
G.-A., Keller ;
Lim, J. E. ;
Edgington, T. S. ;
Shepard, H. M. ;
Patton, J. S. ;
Frost, G. I. .
JOURNAL OF CONTROLLED RELEASE, 2006, 114 (02) :230-241
[10]   Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics [J].
Boswell, C. Andrew ;
Tesar, Devin B. ;
Mukhyala, Kiran ;
Theil, Frank-Peter ;
Fielder, Paul J. ;
Khawli, Leslie A. .
BIOCONJUGATE CHEMISTRY, 2010, 21 (12) :2153-2163